COMMENTARY

• As US Pushes Global Cost Rebalancing, Can Japan Answer with Drug Prices?
  September 7, 2026

• Pharma Faces Wage Challenge in 5% Era as Industry Sustainability at Stake
  September 3, 2026

• Beyond Dupixent: Next Wave of COPD Biologics Takes Shape
  August 25, 2026

• Signs of Shift in Japan’s Drug Policy, but Cost Pressures Persist
  August 3, 2026

• Rare Cancer Case Raises New Questions about AAV Gene Therapy Safety
  July 27, 2026

• A Turning Point for Pharma? Chuikyo Reform Could Open Door to Greater Industry Role
  July 13, 2026

• DORA Use Could Expand as Japan Opens Door to “Sleep Disorders” Specialty
  July 6, 2026

• New Generic Listings Plunge, Industry Heads for a Shakeout
  July 1, 2026

• Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze
  June 16, 2026

• 20 Years at a Glance: Overseas Sales Surge at Japan Pharma, but R&D Investments Lag
  June 9, 2026

• Are Technical Discussions Enough for Japan’s CEA System?
  May 25, 2026

• Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises
  April 28, 2026

• Gene Therapies Expand into AMD, Raising Promise and Cost Concerns
  April 24, 2026

• Challenges in a Post-AG Era: Ensuring a Reliable Supply System
  April 6, 2026

• Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing
  April 1, 2026

• A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste
  March 24, 2026

• Beyond Elevidys: Next-Generation DMD Therapies Advance through Multiple Approaches
  March 11, 2026

• Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause
  March 10, 2026

• ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use
  March 9, 2026

• G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands
  February 25, 2026

ページ